Goldman Sachs has initiated coverage on Edgewise Therapeutics Inc (EWTX) with a Neutral rating, effective September 24, 2025. This marks the firm's first assessment of the clinical-stage biopharmaceutical company, which focuses on developing precision medicines for serious muscle disorders.
Edgewise Therapeutics, headquartered in Boulder, Colorado, is known for its lead product candidate, sevasemten (EDG-5506), an orally administered skeletal myosin inhibitor currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies. The company's pipeline also includes EDG-7500, a novel cardiac sarcomere modulator in Phase II development for hypertrophic cardiomyopathy and other diastolic dysfunction diseases.
As of November 20, 2025, Edgewise has a market capitalization of $2.4 billion and an EPS (TTM) of -1.56. Upcoming earnings are scheduled for August 5, 2026, with an estimated EPS of -0.46 and no expected revenue. Analyst consensus currently shows 6 Strong Buy, 9 Buy, and 4 Hold ratings, reflecting a general positive outlook among analysts.
Analyst ratings serve as professional opinions based on rigorous research and financial models. While they can provide valuable insights, they are based on assumptions that may not always hold true. Investors should consider various factors, including company fundamentals and market trends, when making decisions.